Avasopasem for the treatment of radiotherapy-induced severe oral mucositis

References

• Lalla RV, Brennan MT, Gordon SM, et al. Oral mucositis due to high-dose chemotherapy and/or head and neck radiation therapy. J Natl Cancer Inst Monogr. 2019 Aug 1;2019;(53):17–24.
   Google Scholar
• Rosenthal DI. Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. J Support Oncol. 2007 Oct;5(9 Suppl 4):23–31.
   PubMedGoogle Scholar
• Hoffbauer M, Fineberg J, Stattenfield R, et al. Cost of radiation-induced oral mucositis in head and neck cancer patients: an administrative claims analysis. J Manag Care Spec Pharm. 2020;26:S31.
   Google Scholar
• Caudell JJ, Gillison ML, Maghami E, et al. NCCN guidelines® insights: head and neck cancers, version 1.2022. J Natl Compr Canc Netw. 2022 Mar;20(3):224–234.
   PubMed Web of Science ®Google Scholar
• Noronha V, Joshi A, Patil VM, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol. 2018 Apr 10;36(11):1064–1072. doi: 10.1200/JCO.2017.74.9457
   PubMed Web of Science ®Google Scholar
• Sonis ST. A hypothesis for the pathogenesis of radiation-induced oral mucositis: when biological challenges exceed physiologic protective mechanisms. Implications for pharmacological prevention and treatment. Support Care Cancer. 2021Sep; 29: 4939–4947. Epub 2021 Mar 13. PMID: 33712912;PMCID:PMC8295245. doi: 10.1007/s00520-021-06108-w
   PubMed Web of Science ®Google Scholar
• Sroussi HY, Epstein JB, Bensadoun RJ, et al. Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med. 2017 Dec;6(12):2918–2931.
   PubMed Web of Science ®Google Scholar
• Pulito C, Cristaudo A, Porta C, et al. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. doi: 10.1186/s13046-020-01715-7
   PubMed Web of Science ®Google Scholar
• Yom SS, Torres-Saavedra P, Caudell JJ, et al. Reduced-dose radiation therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol. 2021 Mar 20;39(9):956–965. doi: 10.1200/JCO.20.03128
   PubMed Web of Science ®Google Scholar
• Sheikh S, Kharouta MZ, Pidikiti R, et al. Proton beam therapy for locally advanced head and neck tumors: an analysis of dosimetric and clinical outcomes. Am J Clin Oncol. 2022 Feb 1;45(2):81–87. doi: 10.1097/COC.0000000000000883
   PubMed Web of Science ®Google Scholar
• Sethi S, O’Neil M, Jensen E, et al. Toxicity with proton therapy for oral and/or oropharyngeal cancers: a scoping review. J Oral Pathol Med. Epub ahead of print. PMID: 36871197. 2023 Mar 5. doi: 10.1111/jop.13426
   Web of Science ®Google Scholar
• Sunaga T, Nagatani A, Fujii N, et al. The association between cumulative radiation dose and the incidence of severe oral mucositis in head and neck cancers during radiotherapy. Cancer Rep (Hoboken). 2021 Apr;4(2):e1317.
   PubMedGoogle Scholar
• Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016 Nov;24(11):4825–4830. PMID: 27475958. doi: 10.1007/s00520-016-3337-5
   PubMed Web of Science ®Google Scholar
• Sonis ST. Treatment for oral mucositis—current options and an update of small molecules under development. Curr Treat Options Oncol. 22(3): PMID: 33595722:25. 2021 Feb 17. doi: 10.1007/s11864-021-00823-6
   PubMed Web of Science ®Google Scholar
• Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 351(25). PMID: 15602019. 2590–2598. 2004 Dec 16. doi: 10.1056/NEJMoa040125
   PubMed Web of Science ®Google Scholar
• Nugent M, Bryant V, Butcher C, et al. Photobiomodulation in the management of oral mucositis for adult head and neck cancer patients receiving irradiation: the LiTEFORM RCT. Health Technol Assess. 2022 26;26(46):1–172. doi: 10.3310/UWNB3375
   PubMed Web of Science ®Google Scholar
• Legouté F, Bensadoun RJ, Seegers V, et al. Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial. Radiat Oncol. 14(1). PMID: 31118057; PMCID: PMC6530019. 83. 2019 May 22. doi: 10.1186/s13014-019-1292-2
   PubMedGoogle Scholar
• De Lima AG, Villar RC, de Castro G, et al. Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study. Int J Radiat Oncol Biol Phys. 2012;82(1):270–275. doi: 10.1016/j.ijrobp.2010.10.012
   PubMed Web of Science ®Google Scholar
• Sonis S. Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity? Support Care Cancer. 2020 Feb;28(2):423–424. Epub 2019 Nov 13. Erratum in: Support Care Cancer. 2020 Apr;28(4):2033 Epub 2019 Nov 13. Erratum in: Support Care Cancer. 2020 Apr;28(4):2033. doi: 10.1007/s00520-019-05146-9
   PubMed Web of Science ®Google Scholar
• Silveira FM, Paglioni MP, Marques MM, et al. Examining tumor modulating effects of photobiomodulation therapy on head and neck squamous cell carcinomas. Photochem Photobiol Sci. 2019 Jul 10;18(7):1621–1637. doi: 10.1039/c9pp00120d
   PubMed Web of Science ®Google Scholar
• Elad S, Yarom N, Zadik Y, et al. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022 Jan;72(1):57–77. Epub 2021 Oct 29. PMID: 34714553. doi: 10.3322/caac.21704
   PubMed Web of Science ®Google Scholar
• Lee CT, Galloway TJ. Pathogenesis and amelioration of radiation-induced oral mucositis. Curr Treat Options Oncol. 2022 Mar;23(3):311–324. Epub 2022 Mar 4. PMID: 35244887; PMCID: PMC8931694. doi: 10.1007/s11864-022-00959-z
   PubMed Web of Science ®Google Scholar
• Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010 Oct;16(7):597–600. x. PMID: 20846150. doi: 10.1111/j.1601-0825.2010.01681
   PubMed Web of Science ®Google Scholar
• Nguyen H, Sangha S, Pan M, et al. Oxidative stress and chemoradiation-induced oral mucositis: a scoping review of in vitro, in vivo and clinical studies. Int J Mol Sci. 2022 Apr 27;23(9):4863. doi: 10.3390/ijms23094863
   PubMed Web of Science ®Google Scholar
• Gerschman R, Gilbert DL, Nye SW, et al. Oxygen poisoning and X-Irradiation: a mechanism in common. Science. 1954;119(3097):623–626. doi: 10.1126/science.119.3097.623
   PubMed Web of Science ®Google Scholar
• Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13(5):380–389. PMID: 12393757. doi: 10.1177/154411130201300502
   PubMedGoogle Scholar
• Yeoh A, Gibson R, Yeoh E, et al. Radiation therapy-induced mucositis: relationships between fractionated radiation, NF-κB, COX-1, and COX-2. Cancer Treat Rev. 2006 Dec;32(8):645–651. PMID: 17046165. doi: 10.1016/j.ctrv.2006.08.005
   PubMed Web of Science ®Google Scholar
• Sonis STSuperoxide dismutase as an intervention for radiation therapy-associated toxicities: review and profile of avasopasem manganese as a treatment option for radiation-induced mucositis. Drug Des Devel Ther.2021 Mar 5151021–1029. PMID: 33716500; PMCID:PMC7944116. doi: 10.2147/DDDT.S267400
   PubMed Web of Science ®Google Scholar
• Samlowski WE, Petersen R, Cuzzocrea S, et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med. 2003 Jun;9(6):750–755. Epub 2003 May 5. PMID: 12730689. doi: 10.1038/nm874
   PubMed Web of Science ®Google Scholar
• DiNapoli M, Papa F. M-40403 Metaphore pharmaceuticals. Drugs. 2005;8:67–76.
   PubMedGoogle Scholar
• Murphy CK, Fey EG, Watkins BA, et al. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res. 2008 Jul 1;14(13):4292–4297. doi: 10.1158/1078-0432.CCR-07-4669
   PubMed Web of Science ®Google Scholar
• Beardsley RA, Vasquez Martinez G, Pulliam CF. Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: an exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients. Redox Biol. 2023;60. doi: 10.1016/j.redox.2022.102599
   PubMed Web of Science ®Google Scholar
• Anderson CM, Sonis ST, Lee CM, et al. Phase 1b/2a trial of the superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavity or oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(2):427–435. doi: 10.1016/j.ijrobp.2017.10.019
   PubMed Web of Science ®Google Scholar
• Anderson CM, Lee CM, Saunders DP, et al. Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer. J Clin Oncol. 2019 Dec 1;37(34):3256–3265. doi: 10.1200/JCO.19.01507
   PubMed Web of Science ®Google Scholar
• Anderson CM, Lee CM, Saunders D, et al. Two-year tumor outcomes of a phase 2b, randomized, double-blind trial of avasopasem manganese (gc4419) versus placebo to reduce severe oral mucositis owing to concurrent radiation therapy and cisplatin for head and neck cancer. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):416–421. doi: 10.1016/j.ijrobp.2022.06.063
   PubMed Web of Science ®Google Scholar
• Anderson CM, Lee CM, Kelley JR, et al. Tumor outcomes for ROMAN: phase 3 trial of avasopasem manganese (GC4419) fOr severe oral mucositis (som) in patients receiving chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer (LAHNC). J Clin Oncol. 2022;114(3):S97–S98. doi: 10.1016/j.ijrobp.2022.07.518
   Google Scholar
• Mapuskar KA, Vasquez Martinez G, Pulliam CF, et al. Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: an exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients. Redox Biol. 2023 Jan 3:60:102599. Epub ahead of print. PMID: 36640725; PMCID: PMC9852651. doi: 10.1016/j.redox.2022.102599
   PubMed Web of Science ®Google Scholar
• Anderson CM, Lee CM, Kelley JR, et al. Tumor outcomes for ROMAN: phase 3 trial of Avasopasem manganese (GC4419) for Severe Oral Mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer (LAHNC). Int J Radiat Oncol Biol Phys. 2022;114(3):S97–S98. doi: 10.1016/j.ijrobp.2022.07.518
   Web of Science ®Google Scholar
• Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys PMID: 14967419 2004 Mar 1;58:674–681. doi: 10.1016/S0360-3016(03)01627-4
   PubMed Web of Science ®Google Scholar
• Henke M, Alfonsi M, Foa P, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol Epub 2011 Jun 13. PMID: 21670447 2011 Jul 10;29:2815–2820. doi: 10.1200/JCO.2010.32.4103
   PubMed Web of Science ®Google Scholar
• Le QT, Kim HE, Schneider CJ, et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 29(20). Epub 2011 Jun 13. PMID: 21670453. 2808–2814. 2011 Jul 10. doi: 10.1200/JCO.2010.32.4095
   PubMed Web of Science ®Google Scholar
• Nicolatou-Galitis O, Sarri T, Bowen J, et al. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer. 2013 Jan;21(1):357–364. Epub 2012 Oct 3. PMID: 23052919. doi: 10.1007/s00520-012-1613-6
   PubMed Web of Science ®Google Scholar